Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.
A 16-amino-acid peptide encoded in mitochondrial DNA and studied in relation to metabolism and insulin sensitivity. A 120-participant Phase 2a trial in adults with prediabetes and overweight or obesity began in 2026; it is ongoing and has not reported results.
Carries the strongest 'GLP-1-adjacent' metabolic and longevity narrative, which drives search interest. It is scheduled for FDA committee review on July 23, 2026, while a separate Phase 2a trial is underway.
| Claim | Strongest evidence |
|---|---|
| Metabolism / insulin sensitivity | C Animal |
| Obesity | R Regulatory only |
| Longevity | D Cell / mechanistic |
In its committee briefing, FDA staff said the nominations it reviewed lacked sufficient information and that it did not identify clinical studies evaluating the nominated uses at that review point; staff proposed not adding MOTS-c. Separately, ClinicalTrials.gov now lists an ongoing 120-participant Phase 2a trial with no results posted. An ongoing trial does not establish safety or effectiveness.
No completed robust human trial establishes the marketed uses. The ongoing Phase 2a study has no results yet, and longevity claims still rest mainly on mechanistic or animal reasoning.
No. GLP-1 drugs are approved medicines with large trials; MOTS-c is experimental with limited human data.
Yes. ClinicalTrials.gov lists an ongoing 120-participant Phase 2a trial in adults with prediabetes and overweight or obesity. No results are posted, so it does not yet establish benefit or safety.
Choose your main interest, then get one email when regulatory status changes or strong new evidence lands. Health topics only. Unsubscribe anytime.
Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.